Sirtex Medical Limited (ASX: SRX) has posted a strong lift in net profit to $40.35 million in its latest annual results.
The profit result was a 69 per cent increase on the previous year's $23.8 million figure.
The bio-medical company's revenue was also up by 35.6 per to $177.98 million.
Sirtex is currently working on a treatment for liver cancer and global dose sales of its SIR-Spheres increased by 19.8 per cent for the period.
The company will pay a fully-franked final dividend of 20 cents per share.
top pick in health sector, page-9
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.5¢ |
Change
0.002(15.4%) |
Mkt cap ! $56.76M | |||
| Open | High | Low | Value | Volume |
| 1.3¢ | 1.5¢ | 1.3¢ | $76.04K | 5.442M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 450000 | 1.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.5¢ | 9713598 | 7 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| OSL (ASX) Chart |